Theravance Biopharma TBPH 深 滬
已收盤 07-18 16:00:00 美东时间
11.25
-0.370
-3.18%
華盛通- 最 高11.69
- 今 開11.68
- 成交量 14.44万股
- 最 低 11.235
- 昨 收 11.62
- 總市值 5.63亿
- 52周最高 11.88
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 7.44
- 委 比 6.78%
- 總股本 5000.13万
- 歷史最高 43.44
- 量 比 0.76
- 振 幅 3.92%
- 歷史最低 6.10
- 每 手 1
- 風險率 0.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
BTIG Maintains Buy on Theravance Biopharma, Raises Price Target to $25
BTIG analyst Julian Harrison maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and raises the price target from $24 to $25.
06-27 22:58
Theravance Biopharma Gains Milestone Payment from Viatris
Theravance Biopharma ( ($TBPH) ) has provided an announcement. On June 26, 2025...
06-26 18:28
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Jones Trading Initiates Coverage On Theravance Biopharma with Buy Rating, Announces Price Target of $24
Jones Trading analyst Debanjana Chatterjee initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Buy rating and announces Price Target of $24.
06-17 19:10
Theravance and Mylan settle patent dispute with Eugia Pharma
Theravance Biopharma (NASDAQ:TBPH) and partner Mylan reached a settlement agreement with Eugia Pharma over a patent dispute concerning the lung disease treatment, Yupelri inhalation solution. The comp...
06-06 21:11
美股牛股 | 受益于美国大幅提高钢铁关税，克利夫兰克里夫涨超23%、世纪铝业涨超21%
美国大幅提高钢铁关税，克利夫兰克里夫涨超23.2%、世纪铝业涨超21.3%；Applied Digital大涨48%，与CoreWeave达成长期租赁协议>>
06-03 19:21
Theravance Biopharma Secures $225M In Cash From GSK Deal, Bringing Total Trelegy Monetization Value To $1.525B
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026,
06-02 18:07
Theravance Biopharma Presents Analyses Of Previous Phase 3 Program Evaluating Ampreloxetine For Treatment Of Symptomatic nOH At International MSA Congress
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for
05-10 00:03
